Next Article in Journal
Stereoselective Synthesis and Investigation of Isopulegol-Based Chiral Ligands
Next Article in Special Issue
Combined Treatment with L-Carnitine and Nicotinamide Riboside Improves Hepatic Metabolism and Attenuates Obesity and Liver Steatosis
Previous Article in Journal
Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma Is Reversed by SIRT1
Previous Article in Special Issue
The Number of Liver Galectin-3 Positive Cells Is Dually Correlated with NAFLD Severity in Children
Open AccessReview

Paraoxonase-1 as a Regulator of Glucose and Lipid Homeostasis: Impact on the Onset and Progression of Metabolic Disorders

1
CEDOC—Chronic Diseases Research Center, NOVA Medical School/Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, 1150-082 Lisbon, Portugal
2
ProRegeM PhD Programme, NOVA Medical School/Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, 1150-082 Lisbon, Portugal
3
Faculdade de Ciências e Tecnologias, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal
4
APDP Diabetes Portugal–Education and Research Center (APDP-ERC), 1250-203 Lisbon, Portugal
5
Medical Sciences Department and iBiMED, University of Aveiro, 3810-193 Aveiro, Portugal
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(16), 4049; https://doi.org/10.3390/ijms20164049
Received: 29 July 2019 / Revised: 14 August 2019 / Accepted: 16 August 2019 / Published: 19 August 2019
Metabolic disorders are characterized by an overall state of inflammation and oxidative stress, which highlight the importance of a functional antioxidant system and normal activity of some endogenous enzymes, namely paraoxonase-1 (PON1). PON1 is an antioxidant and anti-inflammatory glycoprotein from the paraoxonases family. It is mainly expressed in the liver and secreted to the bloodstream, where it binds to HDL. Although it was first discovered due to its ability to hydrolyze paraoxon, it is now known to have an antiatherogenic role. Recent studies have shown that PON1 plays a protective role in other diseases that are associated with inflammation and oxidative stress, such as Type 1 and Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease. The aim of this review is to elucidate the physiological role of PON1, as well as the impact of altered PON1 levels in metabolic disorders. View Full-Text
Keywords: PON1; glucose; insulin resistance; diabetes mellitus; NAFLD; obesity PON1; glucose; insulin resistance; diabetes mellitus; NAFLD; obesity
Show Figures

Graphical abstract

MDPI and ACS Style

Meneses, M.J.; Silvestre, R.; Sousa-Lima, I.; Macedo, M.P. Paraoxonase-1 as a Regulator of Glucose and Lipid Homeostasis: Impact on the Onset and Progression of Metabolic Disorders. Int. J. Mol. Sci. 2019, 20, 4049.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop